Pomalidomide in the treatment of patients with plasma cell myeloma based on clinical case analysis
Abstract
Significant progress has been made in the therapy of plasma cell myeloma (PCM) during last
decades. With modern therapies based on proteasome inhibitors or immunomodulatory drugs and
autologous stem cell transplantation we can prolong disease free and overall survival, but not cure
the disease. Treatment of relapsed or refractory PCM should be based on efficacy of proposed drugs,
performance status and patient expectation. The history of the patient treated for many years with
relapsed PCM, with long-term hematological remission with good quality of life after pomalidomide
with dexamethasone is presented in this paper.
Keywords: refractory/relapsed multiple myelomapomalidomidequality of life